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Tumour immunology: T cells work together to fight cancer 
Vincenzo Cerundolo
Recent studies have identified new melanoma antigens
that are recognised by CD4+ T cells. Analysis of tumour-
specific CD4+ T-cell responses may lead to the
development of optimal anti-cancer vaccines that can
induce an orchestrated effort of tumour-specific CD4+
and CD8+ T cells in the fight against cancer.
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A central question in tumour immunology is whether a
tumour-specific immune response is capable of controlling
tumour progression in cancer patients. Although several
animal models have established the role of tumour-spe-
cific CD4+ helper and CD8+ cytotoxic T cells in anti-
tumour immunity, a definitive role for these cells in
tumour-specific immunity in patients with cancer has yet
to be shown. It is likely, however, that a successful anti-
cancer vaccine will need to induce both of the compo-
nents of protective immunity — antibody-mediated and
cell-mediated immune responses. 
To date, the identification of tumour-specific antigens has
been focused almost exclusively on antigens recognised by
tumour-specific CD8+ T cells, which are restricted to
recognising antigens presented by major histocompatibility
complex (MHC) class I molecules. Some of the antigens
recognised by these T cells have been defined at the mole-
cular level, by cloning tumour-specific CD8+ T cells and
using them to screen gene expression libraries derived from
tumour cell lines to find their targets [1]. Alternative strate-
gies have relied on the elution of peptides from MHC class
I molecules and the identification of antigenic peptides by
a combination of chromatographic separation, analysis of
recognition of chromatography fractions by tumour-specific
CD8+ T cells and peptide sequencing [2]. Most of these
tumour antigens were discovered in melanomas, because
cell lines derived from this tumour type can be generated
relatively easily from patient samples. 
Recent data suggest that other tumours may also be sus-
ceptible to immune attack. In particular, the known reper-
toire of tumour antigens is rapidly expanding following
the application of a new approach involving the screening
of tumour-derived expression cDNA libraries for recogni-
tion by high-titre antibodies present in sera of the cancer
patients. This new technique has identified a host of new
antigens recognised by antibodies in cancer patients’ sera.
The fact that a proportion of the antigens isolated using
this approach correspond to those identified in melanoma
patients using CD8+-based techniques suggests that anti-
body responses against tumour antigens may be closely
associated with CD8+ T-cell responses. Development of
new methodologies capable of identifying as yet unknown
tumour antigens is therefore extremely important for
extending our understanding of the immune response to
cancer. These techniques should also make it feasible to
achieve the goal of defining a comprehensive repertoire of
immunogenic gene products expressed by tumour cells. 
Several recent papers have described new strategies to
identify tumour antigens that are recognised by CD4+
T cells in the context of MHC class II molecules [4–8].
Animal models have established the central role played by
CD4+ T cells in inducing tumour regression, even in the
case of tumours that do not express MHC class II mol-
ecules. For example, vaccination of mice with recombi-
nant vaccinia virus encoding the mouse melanocyte
differentiation antigen Trp-1 led to the regression of the
MHC class II negative mouse melanoma B16 [9]. This
anti-tumour response was dependent on CD4+ T cells
because tumour regression did not occur in mice deficient
in MHC class II or in mice depleted of CD4+ T cells by
injection of anti-CD4 monoclonal antibodies. 
In another study, Ossendorp et al. [10] demonstrated that
induction of tumour-specific CD4+ T cells resulted in pro-
tective immunity against virally induced MHC class II
negative tumours. Tumour eradication, however, was
dependent on the induction of tumour-specific CD8+ cyto-
toxic T cells, demonstrating the principle that CD8+ and
CD4+ T-cell responses must act in concert to fight cancer.
The activation of an antigen-specific CD8+ T-cell response
by CD4+ T cells is dependent on the maturation of den-
dritic cells — highly specialised and efficient antigen-pre-
senting cells. Interactions between CD40 expressed on the
dendritic cell and its ligand, CD40L, expressed on CD4+ T
cells [11] can lead to an amplification of the immune
response and tumour destruction. Cytokines secreted by
tumour-specific CD4+ T cells may also lead to tumour
destruction by activating eosinophils and macrophages to
produce superoxide and nitric oxide [12].
The mechanisms by which CD4+ T cells can be activated
by MHC class II negative tumours and induce regression
of MHC class II negative tumours are still ill defined. As
shown for the induction of tumour-specific MHC class I
restricted responses [13], induction of MHC class II
restricted responses specific for MHC class II negative
tumours is controlled by the processing and presentation
of tumour proteins by infiltrating dendritic cells. The find-
ings of Ossendorp et al. [10] demonstrated that this mech-
anism of presentation, defined as cross-presentation, is
also required for the recruitment of anti-tumour effector
cells and the activation of tumour-specific CD8+ T cells
during the rejection of MHC class II negative tumours. 
Constitutive expression of MHC class II molecules is
often observed in human melanomas, which raises the pos-
sibility of whether MHC class II positive tumours may be
directly involved in presenting intracellular antigenic pro-
teins to CD4+ T cells. Can intracellular tumour proteins
have access to the MHC class II presentation pathway and
be presented by the endogenous MHC class II molecules
in the tumour? Analysis of the peptides eluted from MHC
class I and class II molecules showed that there are two
distinct intracellular pools from which MHC class I and
class II molecules can obtain their peptide ligands. The
majority of peptides bound to MHC class I molecules are
derived from cytosolic proteins, whereas the majority of
peptides loaded onto MHC class II molecules are derived
from glycoproteins or secreted proteins. 
This dichotomy of antigen presentation by MHC class I
and class II molecules is central to the current understand-
ing of the T-cell-mediated immune response. It has been
shown, however, that intracellular proteins can actually be
directed into the endosomal compartments for presenta-
tion by MHC class II molecules [14]. Lysosomes are
capable of degrading cytosolic proteins by several mecha-
nisms, including non-specific phagocytosis of cytosolic
proteins, defined as autophagy, and specific selective
protein import pathways for cytosolic proteins [15]. As
these pathways are especially active in cells deprived of
serum or in tissues of starved animals, it is possible that
the processing of tumour proteins and presentation of the
resulting peptides by endogenous MHC class II mol-
ecules in tumours may be more efficient in conditions of
limited blood supply. 
Wang and colleagues [4,5] have described a new strategy
for the identification of tumour antigens presented by
MHC class II molecules. This approach extends a strategy
originally developed by van der Bruggen et al. [1] to iden-
tify MHC class I restricted tumour epitopes because it
directs tumour antigens into the MHC class II presenta-
tion pathway. This pathway of presentation involves the
binding of MHC class II molecules to a molecule termed
the invariant chain in the lumen of the endoplasmic retic-
ulum. These complexes are subsequently targeted into
the endosomal compartment via a motif expressed in the
first 80 amino acids of the invariant chain. Wang and col-
leagues generated a cDNA library from tumour cells that
were capable of stimulating proliferation of an MHC class
II restricted CD4+ T-cell line (Figure 1). MHC class II
positive cells were then transfected with this cDNA
library. To ensure presentation by MHC class II mol-
ecules, the tumour-derived cDNA library had been cloned
downstream of a gene fragment encoding the first 80
amino acids of the invariant chain. A similar approach was
also used by Chaux et al. [6] to identify a CD4+ T-cell
response specific for the tumour antigen MAGE-3 by
expressing full-length MAGE-3 in a retroviral construct
encoding the first 80 amino acids of the invariant chain. 
Application of this strategy has so far led to the identifica-
tion of three MHC class II restricted epitopes: an epitope
contained within a mutated form of the human CDC27
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Figure 1
Outline of the strategy for isolating tumour antigens recognised by
CD4+ T cells. (a) Generation of a cDNA library from a tumour
recognised by an MHC class II restricted CD4+ T-cell clone.
(b) Ligation of cDNA library downstream of the first 80 amino acids of
the invariant chain. (c) Transfection of tumour cDNA library into target
cells expressing appropriate MHC class II molecules. (d) Identification
of target cells capable of activating the tumour-specific CD4+ T-cell
clone. (e) Identification of tumour antigen.
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protein [4]; an epitope from a mutated form of triosephos-
phate isomerase [8]; and an epitope from a protein gener-
ated by the gene fusion of a low density lipid receptor
gene and fucosegalactoside-fucosyltransferase [5]. It is of
interest that the mutated form of CDC27 carries a muta-
tion that affects the phosphorylation site Ser711. This site
is encoded 50 amino acids upstream of the MHC class II
epitope, which corresponds to residues 760–771 and is
conserved between the wild-type and mutated CDC27
protein [4]. As a result of the Ser711 mutation, a large pro-
portion of the CDC27 protein is localised in the cytosol,
whereas wild-type CDC27 is mainly localised in the
nucleus. Cytosolic localisation of the mutated CDC27
protein may account for the presentation of the MHC
class II epitope, because tumour-specific CD4+ T cells
recognised cells transfected with the mutated CDC27 but
not cells transfected with wild-type CDC27. These results
illustrate the principle that mutations or post-translational
modifications of cytosolic proteins may alter their process-
ing and presentation and lead to the generation of MHC
class I and class II epitopes. These findings may have
important implications for the generation of tumour-spe-
cific antigens recognised by CD8+ and CD4+ T cells. 
The application of the strategy described in these recent
papers will undoubtedly speed up the identification of
new tumour-specific antigens and facilitate the generation
of cancer vaccines capable of stimulating both CD4+ and
CD8+ T-cell responses. To optimise the immunogenicity
of cancer vaccines it will also be important to improve the
monitoring of the immune response. The use of
tetrameric soluble peptide–MHC class I complexes
(‘tetramers’) to identify tumour-specific CD8+ T cells has
now shown that these reagents allow rapid and accurate
analysis of human CD8+ T-cell responses in cancer
patients [16]. The development of MHC class II tetramers
will prove to be an invaluable tool for the monitoring of
tumour-specific CD4+ T-cell responses and the develop-
ment of maximally immunogenic cancer vaccines.
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